article thumbnail

Predictors of exposure to high-priority drug-drug interactions among non-elderly adults in Quebec, Canada [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

Population Studied: Community-dwelling non-elderly adults (19-64 years) residents of Quebec and covered by the public prescription drug insurance between 2014 and 2017. Results: Our cohort included 63,834 individuals aged 19-64 (mean age 44.9 Results: Our cohort included 63,834 individuals aged 19-64 (mean age 44.9

article thumbnail

Medicaid expansion is in the eye of the beholder

The Health Policy Exchange

Instead, the Court gave individual states the option to accept or decline the expansion, which, though far more generous with federal matching funds than the existing program, would still require states to spend more within already strapped budgets. Kenny Lin, MD Director, Robert L. Kenny Lin, MD Director, Robert L. Phillips, Jr.

Insurance 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Direct Primary Care - Role for the Future of Healthcare

The Direct Doctors Difference

Looking back to 2014, when we began, there were less than 100. Doctors (and other types of “providers” of healthcare) are tasked with seeing 20-25 patients in an 8 hour day, writing notes that are geared toward insurance billing, and charging for every extra they can manage - all to make the corporate system more profitable.

article thumbnail

Exposure to high-priority drug-drug interactions among non-elderly adults in Quebec: a cohort study [Prescribing and pharmacotherapeutics]

Annals of Family Medicine

DDI exposures were considered incident if the individual was not exposed to a DDI in the year preceding cohort entry. Population: a 5% random sample of adult (19-64y) Quebec residents covered by the public drug insurance in 2014-2017 was used. Results: 1) 11.7% (95% CI: 11.5-12.0) Results: 1) 11.7% (95% CI: 11.5-12.0)

article thumbnail

Time to stop driving? Podcast with Emmy Betz and Terri Cassidy

GeriPal

That’s where it really gets to this individual risks and balances, individual situation. Emmy: Having said that, I think we need to recognize that the gold standard, thorough OT assessment is not a reality for a lot of people, because of there aren’t enough of them, because of insurance might not cover it, and so forth.

IT 102
article thumbnail

Ding Dong is the Skinny Label (Effectively) Dead?

FDA Law Blog

Briefly (more detail is available here ), GSK sued Teva back in 2014 alleging that Teva induced infringement of a method-of-use patent when Teva marketed a skinny-labeled generic version of GSK’s Coreg (carvedilol) as AB-rated. Teva decision changed everything. Par also has filed similar litigation.

IT 52